As of 2025-05-16, the Relative Valuation of Tekla Life Sciences Investors (HQL) is 10.14 USD. This relative valuation is based on P/E multiples. With the latest stock price at 12.10 USD, the upside of Tekla Life Sciences Investors based on Relative Valuation is -16.2%.
The range of the Relative Valuation is 6.62 - 15.17 USD.
| Range | Selected | |
| Trailing P/E multiples | 10.2x - 19.6x | 13.8x |
| Forward P/E multiples | 11.0x - 22.3x | 16.0x |
| Fair Price | 6.62 - 15.17 | 10.14 |
| Upside | -45.3% - 25.4% | -16.2% |
| Date | P/E |
| 2025-05-09 | 15.50 |
| 2025-05-08 | 15.53 |
| 2025-05-07 | 15.67 |
| 2025-05-06 | 15.90 |
| 2025-05-05 | 16.81 |
| 2025-05-02 | 16.81 |
| 2025-05-01 | 16.41 |
| 2025-04-30 | 16.57 |
| 2025-04-29 | 16.25 |
| 2025-04-28 | 16.16 |
| 2025-04-25 | 16.12 |
| 2025-04-24 | 16.29 |
| 2025-04-23 | 15.91 |
| 2025-04-22 | 15.55 |
| 2025-04-21 | 15.19 |
| 2025-04-17 | 15.27 |
| 2025-04-16 | 15.06 |
| 2025-04-15 | 15.19 |
| 2025-04-14 | 15.27 |
| 2025-04-11 | 14.83 |
| 2025-04-10 | 14.39 |
| 2025-04-09 | 14.79 |
| 2025-04-08 | 14.04 |
| 2025-04-07 | 14.31 |
| 2025-04-04 | 14.78 |
| 2025-04-03 | 15.71 |
| 2025-04-02 | 15.90 |
| 2025-04-01 | 15.94 |
| 2025-03-31 | 16.39 |
| 2025-03-28 | 16.64 |
| 2025-03-27 | 16.77 |
| 2025-03-26 | 16.81 |
| 2025-03-25 | 16.91 |
| 2025-03-24 | 17.13 |
| 2025-03-21 | 16.97 |
| 2025-03-20 | 16.82 |
| 2025-03-19 | 16.78 |
| 2025-03-18 | 16.86 |
| 2025-03-17 | 17.03 |
| 2025-03-14 | 16.74 |
| 2025-03-13 | 16.77 |
| 2025-03-12 | 16.75 |
| 2025-03-11 | 16.64 |
| 2025-03-10 | 16.86 |
| 2025-03-07 | 17.08 |
| 2025-03-06 | 16.97 |
| 2025-03-05 | 17.18 |
| 2025-03-04 | 16.83 |
| 2025-03-03 | 17.13 |
| 2025-02-28 | 17.36 |